How the Blood Thinner Apixaban Behaves in Asian People With Atrial Fibrillation
Studies apixaban blood levels and what affects them in Asian adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
Key facts
- Where
- Pathum Wan, ThailandSee the site
Where in Thailand
- Faculty of Medicine, Chulalongkorn UniversityPathum Wan, ThailandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chulalongkorn University
- Trial code
- NCT07747948
- Record updated
- 5 August 2026
- Original description
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation. The main questions it aims to answer are:Read full original descriptionShow less
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation. The main questions it aims to answer are:
1. What are the specific pharmacokinetic parameters and their variabilities for apixaban in this patient population? 2. Which clinical factors, such as kidney function or body weight, are the primary predictors of how apixaban is cleared and distributed in the body?
Participants will be asked to give consent to allow researchers to use their existing electronic outpatient medical records and previously collected blood concentration data for analysis.
Inclusion: Age 18 years and older; Patients diagnosed with atrial fibrillation; Receiving apixaban at a fixed dose of 2.5 mg or 5 mg twice daily for at least 3 consecutive days.
Exclusion: Patients with end-stage renal disease (ESRD) receiving renal replacement therapy; Patients with a history of acute kidney injury (AKI) within 3 months prior to study enrollment; Patients receiving moderate to strong inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp), such as ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, naproxen, clarithromycin, rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort (Patients receiving amiodarone, verapamil, or diltiazem are not excluded and will be included for covariate analysis); Patients with gastrointestinal disorders that significantly affect drug absorption, such as short bowel syndrome; Patients with cirrhosis of Child-Pugh class C severity.